Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 09 Dec 2021
NICE publish final guidance recommending Aspaveli in adults with ultra rare blood disorder
9 December 2021 - The medicine is additionally undergoing assessment with the Medicines and Healthcare products Regulatory Agency for a ...
Posted by Michael Wonder on 09 Dec 2021
COVID-19 vaccine weekly safety report (9 December 2021)
9 December 2021 - To 5 December 2021, the TGA has received 389 reports which have been assessed as likely to ...
Posted by Michael Wonder on 09 Dec 2021
FDA authorises new long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain individuals
8 December 2021 - Today, the U.S. FDA issued an emergency use authorization for AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab and ...
Posted by Michael Wonder on 08 Dec 2021
Don’t destroy future drug development
8 December 2021 - With support faltering for the massive big-government blowout Congress is trying to jam through by Christmas, ...
Posted by Michael Wonder on 08 Dec 2021
FoundationOne CDx receives FDA approval as a companion diagnostic for BRAF inhibitor therapeutics in melanoma
8 December 2021 - Foundation Medicine’s tissue-based test is the first and only comprehensive genomic profiling test to be approved as ...
Posted by Michael Wonder on 08 Dec 2021
PhRMA statement on White House drug pricing event
6 December 2021 - Pharmaceutical Research and Manufacturers of America President and CEO Stephen J. Ubl released the following statement ...
Posted by Michael Wonder on 08 Dec 2021
FDA takes new steps aimed at advancing development of individualised medicines to treat genetic diseases
7 December 2021 - Today, the FDA is issuing a draft guidance to provide recommendations for managing the administration of individualised ...
Posted by Michael Wonder on 08 Dec 2021
Funding Keytruda for melanoma but not for lung cancer is racist, health advocates say
8 December 2021 - PHARMAC has been accused of institutional racism and breaching the Treaty of Waitangi for funding drugs ...
Posted by Michael Wonder on 08 Dec 2021
$56K Alzheimer’s drug avoiding Biden’s cost curbs, for now
8 December 2021 - A new $56,000 a year Alzheimer’s medication that’s leading to one of the biggest increases ever in ...
Posted by Michael Wonder on 08 Dec 2021
Pfizer will submit full data on Covid treatment pill to the FDA in a few days, CEO says
8 December 2021 - Pfizer CEO Albert Bourla said he’s confident the full results from the clinical trials will show that ...
Posted by Michael Wonder on 08 Dec 2021
NICE terminates appraisal of yet another cancer medicine
7 December 2021 - NICE is unable to make a recommendation on the use of olaparib (Lynparza) on the NHS for ...
Posted by Michael Wonder on 08 Dec 2021
TGA approves booster doses of the Moderna COVID-19 vaccine Spikevax
8 December 2021 - The TGA has provisionally approved a booster dose of the Moderna COVID-19 vaccine, SPIKEVAX, for individuals ...
Posted by Michael Wonder on 08 Dec 2021
Novavax COVID-19 vaccine could be approved very soon, says EMA chief
8 December 2021 - The head of the EMA on Tuesday said that it could soon approve the COVID-19 vaccine ...
Posted by Michael Wonder on 08 Dec 2021
Improvements to clinical trials will strengthen Australia’s economy and benefit patients
8 December 2021 - Clinical trials in Australia need improvements if we are to increase our global competitiveness says Medicines ...
Posted by Michael Wonder on 08 Dec 2021
New therapies for a range of conditions are coming in 2022
8 December 2021 - Haemophilia, brain disorders and malaria are being targeted. ...